Literature DB >> 23471031

Paraoxonase-1 status in patients with hereditary hemochromatosis.

Nicola Martinelli1, Anabel García-Heredia, Helena Roca, Núria Aranda, Victoria Arija, Bharti Mackness, Michael Mackness, Fabiana Busti, Gerard Aragonès, Juan Pedro-Botet, Federica Pedica, Ivana Cataldo, Judit Marsillach, Jorge Joven, Domenico Girelli, Jordi Camps.   

Abstract

Hereditary hemochromatosis (HH) is characterized by accumulation of iron, oxidative stress, inflammation, and fibrogenesis in liver tissue. In this setting, research on the protection afforded by intracellular antioxidants is of clinical relevance. Paraoxonase-1 (PON1) is an enzyme that degrades lipid peroxides. This study investigates the alterations in serum PON1 status, PON1 gene polymorphisms, and PON1 hepatic expression in patients with HH. We performed a case-control study in 77 patients with HH (80.5% men, 22-70 years of age) and 408 healthy individuals (43.1% men, 26-74 years of age). Serum PON1 activities against different substrates and PON1192 and PON155 polymorphisms were analyzed. PON1 protein expression was investigated in 20 liver biopsies. HH patients had significantly lower serum PON1 activity, which was inversely correlated with ferritin (marker of iron stores) and serum 8-isoprostane concentrations (index of oxidative stress). PON1 protein expression in liver tissue was higher in patients and showed stronger staining in hepatocytes surrounding the areas of inflammation. Our study provides preliminary evidence that PON1 may play a role in protecting against iron-induced oxidative stress in hereditary hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471031      PMCID: PMC3622340          DOI: 10.1194/jlr.P028977

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  52 in total

1.  Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage.

Authors:  Natàlia Ferré; Jordi Camps; Eduard Prats; Elisabet Vilella; Antoni Paul; Lídia Figuera; Jorge Joven
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

2.  Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells.

Authors:  Yoshitaka Kumon; Yuh Nakauchi; Tadashi Suehiro; Tomoko Shiinoki; Noriyasu Tanimoto; Mari Inoue; Toshihiro Nakamura; Kozo Hashimoto; Jean D Sipe
Journal:  Amyloid       Date:  2002-09       Impact factor: 7.141

3.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

4.  Oxidative damage in colon and mammary tissue of the HFE-knockout mouse.

Authors:  Richard G Stevens; James E Morris; Gerald A Cordis; Larry E Anderson; Daniel W Rosenberg; Lyle B Sasser
Journal:  Free Radic Biol Med       Date:  2003-05-01       Impact factor: 7.376

5.  Clinical expression and insulin sensitivity in type 2 diabetic patients with heterozygous mutations for haemochromatosis.

Authors:  S Van Lerberghe; M P Hermans; K Dahan; M Buysschaert
Journal:  Diabetes Metab       Date:  2002-02       Impact factor: 6.041

6.  Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6.

Authors:  B J Van Lenten; A C Wagner; M Navab; A M Fogelman
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

7.  Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies.

Authors:  Dai-Hua Fang; Cong-Hai Fan; Qiang Ji; Bo-Xiang Qi; Juan Li; Lu Wang
Journal:  Mol Biol Rep       Date:  2012-02-10       Impact factor: 2.316

8.  Serum ferritin and risk of the metabolic syndrome in U.S. adults.

Authors:  Megan Jehn; Jeanne M Clark; Eliseo Guallar
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

9.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes.

Authors:  Michal Harel; Amir Aharoni; Leonid Gaidukov; Boris Brumshtein; Olga Khersonsky; Ran Meged; Hay Dvir; Raimond B G Ravelli; Andrew McCarthy; Lilly Toker; Israel Silman; Joel L Sussman; Dan S Tawfik
Journal:  Nat Struct Mol Biol       Date:  2004-04-18       Impact factor: 15.369

10.  Antioxidant paraoxonase 1 activity in the metabolic syndrome.

Authors:  Mariano Sentí; Marta Tomás; Montserrat Fitó; Tanja Weinbrenner; María-Isabel Covas; Joan Sala; Rafel Masiá; Jaume Marrugat
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  10 in total

1.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

2.  Trace Elements and Paraoxonase-1 Activity in Lower Extremity Artery Disease.

Authors:  Joaquim Rovira; Anna Hernández-Aguilera; Fedra Luciano-Mateo; Noemí Cabré; Gerard Baiges-Gaya; Martí Nadal; Vicente Martín-Paredero; Jordi Camps; Jorge Joven; José L Domingo
Journal:  Biol Trace Elem Res       Date:  2018-03-10       Impact factor: 3.738

3.  Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria.

Authors:  S Iftimie; A García-Heredia; I Pujol; F Ballester; I Fort-Gallifa; J M Simó; J Joven; J Camps; A Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-22       Impact factor: 3.267

4.  Status of Superoxide Dismutase in Transfusion Dependent Thalassaemia.

Authors:  Lantip Rujito; Sri Mulatsih; Abdul Salam M Sofro
Journal:  N Am J Med Sci       Date:  2015-05

5.  Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma.

Authors:  Hikmet Akkız; Sedef Kuran; Ersin Akgöllü; Oğuz Üsküdar; Aynur Bekar; Süleyman Bayram; Selçuk Yıldırım; Yakup Ülger; Berrin Yalınbaş Kaya; Mahmut Şansal; Ercan Çınar
Journal:  Meta Gene       Date:  2013-10-28

6.  Iron overload by Superparamagnetic Iron Oxide Nanoparticles is a High Risk Factor in Cirrhosis by a Systems Toxicology Assessment.

Authors:  Yushuang Wei; Mengzhu Zhao; Fang Yang; Yang Mao; Hang Xie; Qibing Zhou
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

7.  Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients.

Authors:  Meritxell Arenas; Anabel García-Heredia; Noemí Cabré; Fedra Luciano-Mateo; Anna Hernández-Aguilera; Sebastià Sabater; Marta Bonet; Marina Gascón; Salvador Fernández-Arroyo; Isabel Fort-Gallifa; Jordi Camps; Jorge Joven
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

8.  Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease.

Authors:  Anna Hernández-Aguilera; Salvador Fernández-Arroyo; Noemí Cabre; Fedra Luciano-Mateo; Gerard Baiges-Gaya; Montserrat Fibla; Vicente Martín-Paredero; Javier A Menendez; Jordi Camps; Jorge Joven
Journal:  Mediators Inflamm       Date:  2018-09-20       Impact factor: 4.711

9.  A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease.

Authors:  Boštjan Petrič; Tanja Kunej; Aljoša Bavec
Journal:  OMICS       Date:  2020-12-11

10.  Lactonase Activity, Status, and Genetic Variations of Paraoxonase 1 in Women with Gestational Diabetes Mellitus.

Authors:  Mi Zhou; Xing-Hui Liu; Qing-Qing Liu; Meng Chen; Huai Bai; Lin-Bo Guan; Ping Fan
Journal:  J Diabetes Res       Date:  2020-02-03       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.